Renin-angiotensin-aldosterone system inhibitors (RAASis) have been shown to reduce blood pressure and proteinuria [1], delay estimated glomerular filtration rate (eGFR) decline [2], and lower the risk of kidney failure, cardiovascular morbidity, and all-cause mortality in patients with chronic kidney disease (CKD) [2]. Here, REN is linked to chronic kidney disease.